Neuroendocrine tumors account for approximately 20% of lung cancers; most (≈15%) are small cell lung cancer (SCLC). These NCCN Clinical Practice Guidelines in Oncology for SCLC focus on extensive-stage SCLC because it occurs more frequently than limited-stage disease. SCLC is highly sensitive to initial therapy; however, most patients eventually die of recurrent disease. In patients with extensive-stage disease, chemotherapy alone can palliate symptoms and prolong survival in most patients; however, long-term survival is rare. Most cases of SCLC are attributable to cigarette smoking; therefore, smoking cessation should be strongly promoted. Copyright © 2013, JNCCN-Journal of the National Comprehensive Cancer Network.
CITATION STYLE
Kalemkerian, G. P., Akerley, W., Bogner, P., Borghaei, H., Chow, L. Q., Downey, R. J., … Hughes, M. (2013). Small cell lung cancer: Clinical practice guidelines in oncology. JNCCN Journal of the National Comprehensive Cancer Network, 11(1), 78–98. https://doi.org/10.6004/jnccn.2013.0011
Mendeley helps you to discover research relevant for your work.